Bifunctional IL-2 Cytokine Fusions for Dual-Receptor Tumor Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for bispecific IL-2 cytokine fusions that can address the technical problem of enhancing immune activation and homeostasis, particularly in addressing the challenges of existing technologies that have not been effectively addressed in the art for existing technologies.
Innovation Solution
The technical solution is the development of bifunctional molecules that include combinations of IL-2, IL-4, and IL-13 based on specific combinations of IL-2, IL-4, and IL-5, IL-7, IL-12, IL-15, and IL-18, or IL-18, or IL-2, IL-5, IL-12, IL-15, IL-18, and IL-33 based amino acid sequences of the bifunctional molecule comprising specific measures or methods taken to solve the aforementioned technical problems.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bisspecific IL-2 cytokine fusions are developed to enhance immune activation, then immune response effectiveness is improved, but molecular complexity and manufacturing difficulty increase
Solution Approach 1:
The patent combines IL-2 cytokine with another cytokine (IL-4, IL-5, IL-7, IL-12, IL-15, IL-18, or IL-33) into a single bifunctional molecule. This merging approach allows the molecule to simultaneously engage multiple receptor pathways (IL-2Rβγ and another cytokine receptor), thereby enhancing immune activation effectiveness while delivering two therapeutic functions from one molecular entity rather than requiring separate administration of multiple cytokines.
Solution Approach 2:
The bifunctional molecule is designed to perform multiple functions: it retains IL-2's ability to activate CD8+ T cells and NK cells while simultaneously providing the secondary cytokine's functions (such as IL-4's anti-inflammatory effects or IL-7's T cell survival signals). This multi-functionality allows a single molecule to address multiple aspects of immune regulation and tumor immunity that would otherwise require separate therapeutic agents.
2Reliability
If bifunctional molecules with multiple cytokine combinations are created, then immune activation and homeostasis are enhanced, but manufacturing precision and production difficulty increase
Solution Approach 1:
The patent merges multiple cytokine functions into a single genetically engineered polypeptide chain. The bifunctional molecule comprises an IL-2 portion (amino acids 1-133) fused to a second cytokine portion, creating one continuous polypeptide that can be produced in a single recombinant expression system. This approach simplifies manufacturing compared to producing separate cytokines and formulating them as a mixture, as it ensures precise stoichiometry and stable association of both functional domains.
Solution Approach 2:
The patent employs specific amino acid substitutions in the IL-2 portion (L80F, R81D, L85V, 186V, 192F) to modify binding characteristics. These parameter changes in the molecular structure enhance binding affinity for IL-2Rβγ receptor while maintaining the ability to engage the second cytokine receptor, thereby optimizing the bifunctional molecule's effectiveness without requiring complex post-manufacturing adjustments.
3Reliability
If IL-2 binding affinity to IL-2Rβ is increased through mutations, then immune cell activation is improved, but specificity and potential off-target effects may be compromised
Solution Approach 1:
The patent applies specific amino acid substitutions at particular positions in the IL-2 sequence (L80F, R81D, L85V, 186V, 192F) to locally modify the binding interface. These localized changes enhance affinity for IL-2Rβγ while the bifunctional design ensures that the molecule also requires engagement of the second cytokine receptor for full activity, thereby maintaining a degree of specificity through dual-receptor dependence.
Solution Approach 2:
The bifunctional molecule acts as an intermediary that bridges two receptor systems. By requiring simultaneous or sequential engagement of both the IL-2Rβγ complex and the second cytokine's receptor, the molecule creates a more specific signaling pathway that reduces the likelihood of off-target effects compared to wild-type IL-2, which can bind to multiple receptor variants including the high-affinity IL-2Rαβγ complex.
Data Source
AI summary
Human interleukin-2 (IL-2), Human interleukin-13 (IL-13), and/or Human interleukin-4 (IL-4) cytokine fusions are provided. In particular, provided are IL-2, IL-4, and/or IL-13 cytokine fusions for use in monotherapeutic applications as well as in combination therapies for the treatment of cancer. Also provided are pharmaceutical compositions that include such IL-2 IL-4, and/or IL-13 cytokine fusions.